Epstein-Barr virus (EBV) is a ubiquitous DNA virus that normally infects silently, establishing lifelong latency. Substantial empirical observations support the view that immunodeficiency is permissive in EBVinduced lymphoproliferative diseases (LPD). Primary immune deficient patients such as those with Xlinked lymphoproliferative disease and individuals with acquired immune deficiency secondary to immunosuppressive drugs for organ transplantation or individuals infected with human immunodeficiency virus are also at very high risk for lethal LPD. The importance of immunodeficiency and EBV in the development of head and neck carcinomas and uterine cervical carcinoma is less clear. Methods are available for detecting immunodeficiency and EBV genome and thus preventive strategies are being developed to preclude LPD from occurring.
Introduction
Milestones in the discovery of Epstein-Barr virus (EBV)-induced diseases include description of Burkitt's lymphoma (BL) by Denis Burkitt in 1958, the discovery of the EBV 25 years ago by Anthony Epstein, Burt Achong, and Yvonne Barr, the serological association of EBV with nasopharyngeal carcinoma (NPC) by Lloyd Old in 1966, and the discovery that EBV causes infectious mononucleosis (IM) by the Henles in 1968 (1) .
Until about the mid-1970s, the two prevailing hypotheses regarding the oncogenicity of EBV included the notion that benign and malignant strains of EBV prevailed or, alternatively,. that immunodeficiency played a major role in the development of certain malignancies (2) . Supporting the latter hypothesis was our discovery in 1975 of the X-linked lymphoproliferative disease (XLP) (3), wherein affected males develop fatal IM, malignant lymphoma, or acquired agammaglobulinemia following infection by EBV. Furthermore, XLP provided clues to the cause of malignant lymphoma found earlier by Starzl in renal transplant recipients (4) , and Gatti and Good also had found a very high prevalence of malignant lymphoma in immune-deficient children (5) .
Summarized herein are the roles of immunodeficiency in the development of EBV-induced lymphoproliferative diseases (LPD). The mechanisms responsible for the evolution of these diseases at cytogenetic and molecular levels and the findings of EBV-carrying carcinomas involving the head and neck and uterine cervix are described. A brief background including the molecular anatomy of EBV and normal immune responses to the virus is outlined.
Immunobiology of EBV
EBV is a DNA virus of 172 kb. It gains access to the human epithelium in the oropharyngeal region through CR2 receptors. Within the squamous epithelium, the virus is able to undergo productive infection. Intimate association of the lymphoid tissues with the oral epithelium permits infection of the human B-cell, which can be immortalized (6) . Most individuals become asymptomatically infected during childhood, and lifelong latency is established.
The virus is composed of about 100 genes, which are currently being mapped (Fig. 1) neapolis, and elsewhere to determine whether EBV is responsible for LPD in organ transplant recipients and children with primary immunodeficiency. The results of these collaborative studies were published in a special edition of Cancer Research in 1981 (10) and in a monograph (11) .
These collaborative studies disclosed the LPD found in renal transplant recipients is due to EBV. In young patients, LPD tends to be disseminated but with time can evolve into a malignant lymphoma (12) . This is likely due to primary infection occurring in the young patients leading to an IM-like disease. In contrast, elderly individuals who have latent virus undergo reactivation of EBV owing to immunosuppression. These patients are more apt to develop solitary masses in extranodal sites.
Recognition that EBV is the cause of LPD in organ transplant recipients has permitted development of strategies to prevent and treat individuals with this complication. For example, withdrawal of immunosuppression can lead to regression of the LPD in cases where the proliferation is polyclonal (13) . Furthermore, use of acyclovir can be beneficial in some instances (12) . Early diagnosis of LPD can also lead to prevention of the malignant lymphoma ( Table 1) .
The use of high-dose cyclosporin and monoclonal an- (14) . Methods must be developed to obviate these deadly consequences of immunosuppression. Individuals infected with human immunodeficiency virus (HIV) are at high risk for developing EBV-induced diseases including hairy leukoplakia of the tongue, persistent lymphadenopathy, pulmonary lymphoid interstitial pneumonia (LIP), hyperplasia of the lymphoid tissue in the colon, and malignant B-cell lymphomas. An estimated 1,000-fold increase of B-cell lymphomas occurs in individuals infected with HIV (15) . Approximately one-half of these lymphomas carry EBV genome. Similarly, the LIP lesion in the lungs of children with AIDS is due to EBV. It is likely that long-term survivors with HIV infection will be at increasingly high risk of developing EBV-driven LPD.
We and others have demonstrated that children with immunodeficiency diseases have a markedly increased risk for EBV-driven LPD. This ranges from about 2% for children with Bruton's agammaglobulinemia to about 25% for males with XLP (16). Our laboratory focuses on XLP, and so a summary of the disease will be provided as a model for studying immunodeficiency and EBV-induced LPD. The males who develop malignant lymphoma following EBV infection generally have the BL-like type involving the ileocecal region, central nervous system, or other extranodal sites (20) . Survival is often long-term, especially in those who concurrently exhibit hypogammaglobulinemia (17) .
LPD in Patients with
Recently we have mapped the XLP locus using DNA probes in the X chromosome, especially DXS42, DXS37, and DXS10. These probes have restriction length polymorphisms (RFLP) and link tightly with the XLP locus (21) . We have also identified a family in Omaha with a deletion involving the XLP locus at Xq25 (22) . These findings allow us to make accurate diagnoses and to provide genetic counseling and immunoprophylaxis with IV immunoglobulin containing antibodies to EBV.
Mechanisms of Polyclonal to
Monoclonal B-Cell Conversion Klein (23) has hypothesized that EBV drives polyclonal B-cell proliferation and that breakage and reciprocal translocation involving chromosomes 8 (c-myc), 14 (heavy chain), 22 (lambda), and 2 (kappa) are involved in development of BL. Klein and colleagues have also demonstrated a similar condition in rats and mice plasmacytomas. Moreover, a molecular contruct of Ig-myc when in transgenic mice results in malignant pre-B and B-cell lymphomas in the mice. These mice are patented and can be purchased for studies.
That immunodeficiency is permissive of EBV-induced malignant lymphoma is attested to by studies demonstrating immunodeficiency and EBV-containing malignant lymphoma in children infected with malaria and EBV in the BL belt, organ transplant recipients, AIDS victims, and immune-deficient children (24) . Furthermore, recent studies in the severe combined immunodeficiency (SCID) mouse demonstrate that when peripheral blood mononuclear cells are engrafted from an EBV seropositive individual, the mice eventually develop lethal LPD (25) . The foregoing conditions are all characterized by T-cell deficiency allowing EBV to drive B-cell proliferation in a sustained manner.
EBV-Induced Carcinomas
The EBV genome was first found in 1970 by Zur Hausen (26) in nasopharyngeal carcinoma (NPC) and subsequently Brichacek has demonstrated the virus in supraglottic tumors and tonsillar carcinomas (27, 28) and occasional thymomas (29) . Our inability to explain how EBV infection during infancy could be responsible for NPC in adults has been perplexing. Surely, immunologic and genetic factors play a role in allowing NPC to develop. The tumor develops primarily in Chinese males. Males have a relative immune deficiency com- (35) (36) (37) . Finally, BL cells express certain cell adhesion molecules at lower levels than the corresponding lymphoblastoid cells (38) . Klein has speculated that these differences between the BL and the lymphoblastoid cells provide immunoselection advantage with resistance to cytotoxic T-cells (Table 2 ). (39) , and more recently, high-dose immunoglobulin and interferon alpha, with limited success (40). Shapiro et al. (41) have successfully treated immunodeficient children with these agents.
Development of a vaccine against EBV membrane antigen (GP340) has resulted in some protection of cotton-topped tamarins against primary EBV infection (42) (43) (44) (45) 
